BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Goldman Sachs initiates Aurobindo Pharma with buy
Approvals to drive growth for Aurobindo. Valuations compelling at 15 per cent discount to sector average. Expect operating margins to increase by 280 basis points.